Zai Labの空売り状況は、投資家がZai Labの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Zai Lab (OTC:ZAILF) 株価情報, 空売り情報

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Zai Lab Ltd

News

Guidance

Nordstrom Continues To Expect FY24 Adjusted EPS Of $1.75 - $2.05 (Est $1.89)

WIIM

DELL

Dell Technologies shares are trading lower following a Q3 revenue miss.

WDAY

Workday shares are trading lower after the company revised its FY25 subscription revenue guidance,

NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because it had not timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q") with the Securities and Exchange Commission (the "SEC") on or before November 19, 2024, the extended period provided for the filing under Rule 12b-25(b) of the Securities Exchange Act of 1934, as amended. The delay is in part due to the additional time required for valuation and review of various derivative securities as the Company has taken on more reporting responsibility internally. The Notice from Nasdaq has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market.
The Company is actively working with its auditors and advisors and intends to file the Form 10-Q as promptly as possible.
On November 20, 2024, subsequent to the Company's receipt of the Notice, the Company received a letter from Nasdaq (the "Decision Letter") granting a temporary exception to the Rule and the minimum market value of listed securities requirement in Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Rule") until January 7, 2025. The Seoul Bankruptcy Court (the "Court") is expected to announce its decision on the rehabilitation of NKMax Co. Ltd ("NKMax") and the Company's proposal to acquire a majority interest in NKMax on or before such date. In accordance with the Decision Letter, the Company must advise the Nasdaq Hearings Panel (the "Panel") of the outcome of the Court's decision. If the Company is successful in its bid to acquire a majority interest in NKMax, the Company must advise the Panel no later than January 7, 2025, on its plan for regaining compliance with the Rule and MVLS Rule, for the Panel's further consideration.
The Company may request that the Nasdaq Listing and Hearing Review Council (the "Council") review the Panel's determination in the Decision Letter, by written request received by the Council by December 5, 2024. In such event, the Company would be required to submit a fee of $15,000.00 to Nasdaq to cover the cost of the review. The Council may determine to review any Panel decision by January 4, 2025. The Company does not intend to appeal the Decision Letter at this time and intends to deliver an updated plan of compliance to the Panel no later than January 7, 2025.

NKGN

NKGen Biotech Receives Notifications From Nasdaq Related To Delayed Quarterly Report And Decision Of The Nasdaq Hearings Panel; The Company Does Not Intend To Appeal The Decision Letter At This Time And Intends To Deliver An Updated Plan Of Compliance To The Panel No Later Than January 7, 2025.

For fiscal 2025, HP anticipates generating free cash flow in the range of $3.2 to $3.6 billion.

HP Expects Adj EPS Of $0.70 - $0.76 For Q1 (Est $0.85); $3.45 - $3.75 For FY25 (Est $3.60)

Guess Sees FY25 EPS $0.70-$0.82; Adj. EPS $1.85-$2.00.

<a href="https://www.globenewswire.com/Tracker?data=RStI-Eh5ZELBq7ZL7G-QBxlErYxTLAPvtV51a1k8H3KnWszbj2ti19uebhw7GWFQ3ce_q6rFvE8kHIB45a22cePjTzLcXiJ3Yvs4Bydq8dE=">Middlesex Water Company</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>), a provider of water and wastewater and related services primarily in New Jersey and Delaware, today announced that Gregory Sorensen has been named as its Vice President and Chief Operating Officer, effective December 16, 2024, as part of ongoing strategic succession planning and organizational realignment efforts.

Management

MSEX

Middlesex Water Names Gregory Sorensen VP And COO, Effective December 16, 2024, As Part Of Ongoing Strategic Succession Planning And Organizational Realignment Efforts.

Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) reported quarterly losses of $(0.52) per share. This is unchanged from the same period last year. The company reported $4.22 million in sales this quarter. This is a 2.10 percent increase over sales of $4.14 million the same period last year.

Earnings

Regional Health Props Q3 EPS $(0.52), Same YoY, Sales $4.22M Up From $4.14M YoY

Guess? Q3 2025 Adj. EPS $0.34 Down From $0.49 YoY, Sales $739.0M Up From $651.1M YoY

The earnings results for Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) for Q3 were made public on Tuesday, November 26, 2024 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Urban Outfitters beat estimated earnings by 28.999999999999996%, reporting an EPS of $1.1 versus an estimate of $0.85.
Revenue was up $81.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
Last quarter the company beat on EPS by $0.24 which was followed by a 10.0% drop in the share price the next day.
Here's a look at Urban Outfitters's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1</td>
<td>0.51</td>
<td>0.73</td>
<td>0.82</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.24</td>
<td>0.69</td>
<td>0.69</td>
<td>0.88</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.34B</td>
<td>1.17B</td>
<td>1.49B</td>
<td>1.26B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.35B</td>
<td>1.20B</td>
<td>1.49B</td>
<td>1.28B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Urban Outfitters <a href="https://www.benzinga.com/quote/URBN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

URBN

Earnings Summary: Urban Outfitters Q3

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) just disclosed its Q4 earnings on Tuesday, November 26, 2024 at 04:15 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
HP missed estimated earnings by 0.0%, reporting an EPS of $0.93 versus an estimate of $0.93.
Revenue was up $238.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
Last quarter the company missed on EPS by $0.03 which was followed by a 2.0% increase in the share price the next day.
Here's a look at HP's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.86</td>
<td>0.81</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.83</td>
<td>0.82</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>13.38B</td>
<td>12.60B</td>
<td>13.51B</td>
<td>13.81B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>13.52B</td>
<td>12.80B</td>
<td>13.19B</td>
<td>13.82B</td>
</tr>
</tbody>
</table>

To track all earnings releases for HP <a href="https://www.benzinga.com/quote/HPQ/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HP Earnings Report: Q4 Overview

- SAN711 is a first-in-class, highly selective GABAA-α3 positive allosteric modulator
- Targeting initiation of Phase 2 study of SAN711 for the treatment of essential tremor in 2026
Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. Acadia is planning to initiate a Phase 2 study of SAN711 in essential tremor in 2026.
"Licensing SAN711 to expand our pipeline underscores our unwavering commitment to delivering innovative therapies for patients with central nervous system disorders," said Catherine Owen Adams, Chief Executive Officer. "Essential tremor is a condition that has not seen innovation in treatment for decades, creating a compelling opportunity to address a long-overlooked need. Our work with SAN711 will draw on our deep expertise in developing and commercializing cutting-edge treatments for neurological disorders."
Under the terms of the License Agreement, Saniona will receive US $28 million upfront plus potential milestone payments of up to US $582 million. In addition, Saniona is eligible to receive tiered royalties of mid-single digits to low double digits on net sales of commercial products that may result from development of SAN711. The potential milestone payments to Saniona consist of up to US $147 million subject to achievement of development and commercial milestones related to potential first and second indications, and up to US $435 million subject to achievement of thresholds of annual net sales of SAN711 worldwide. Acadia will lead further clinical development, regulatory submissions, and global commercialization efforts for SAN711 while also providing financial support for Saniona's ongoing Phase 1 study and preparations for Phase 2.

Biotech

Contracts

General

ACAD

Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M

The quarterly cash dividend is payable on January 2, 2025 to stockholders of record as of the close of business on December 11, 2024. This is the first dividend of HP's 2025 fiscal year and represents an increase of 5% from the prior dividend.

Dividends

HP Raises Annual Dividend By 5%; Boosts Quarterly Cash Dividend From $0.2756 To $0.2894 Per Share

Buybacks

Installed Building Products Repriced $500M Loan

Financing

EVTV

Envirotech Vehicles Expects $25M Funding From Yorkville Advisors Global

Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) reported quarterly losses of $(1.26) per share. This is a 78.28 percent increase over losses of $(5.80) per share from the same period last year.

PRTG

Portage Biotech Q2 EPS $(1.26) Up From $(5.80) YoY

Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) reported $49.60 million in sales this quarter.

IREN

Iris Energy Q1 Sales $49.60M

Offerings

SCNX

Scienture Holdings Announces Private Placement Of $3M of 10% Secured Convertible Debentures As Initial Tranche Of $12M Offering And Entry Into $50 Million Equity Line Of Credit Agreement

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) reported quarterly earnings of $0.93 per share which met the analyst consensus estimate. This is a 3.33 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $14.05 billion which beat the analyst consensus estimate of $13.99 billion by 0.49 percent. This is a 1.72 percent increase over sales of $13.82 billion the same period last year.

Comments

Zai Lab

空売り

Zai Lab (OTC:ZAILF) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル